Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coya TherapeuticsCOYA -3.10%49 Interest Coverage is No Debt (1) as of Jun. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates COYA with a GF Score™ of 49/100 and a GF Value™ of $6.54 (Significantly Undervalued). Among 368 Biotechnology companies, Coya Therapeutics ranks better than 98.91% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Coya Therapeutics's
Operating Income
for the
three
months ended in Jun. 2026 was $-7.05 Mil. Coya Therapeutics's Interest Expense for the
three
months ended in Jun. 2026 was $0.00 Mil.
Coya Therapeutics has no debt.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Coya Therapeutics Inc has no debt.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Coya Therapeutics's Interest Coverage or its related term are showing as below:
COYA'
s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt
COYA's Interest Coverage is ranked better than 98.91% of 368
companies
in the Biotechnology industry
Industry Median: 98.255
vs COYA: No Debt
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Coya Therapeutics Interest Coverage Related Terms
Coya Therapeutics Interest Coverage Historical Data
* Premium members only.
The historical data trend for Coya Therapeutics's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
COYA vs ONCY, GUTS, SEER: Interest Coverage Comparison
For the Biotechnology subindustry, Coya Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coya Therapeutics Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coya Therapeutics's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Coya Therapeutics's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Coya Therapeutics (COYA) has a Interest Coverage of No Debt (1) as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Coya Therapeutics and its competitors. This is 100% below median its historical median of 10,000.00. Over the past decade, Coya Therapeutics' Interest Coverage has ranged from 10,000.00 to 10,000.00. According to the industry distribution chart, Coya Therapeutics ranks #4 out of 368 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Coya Therapeutics' Interest Coverage too high?
Coya Therapeutics' current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 10,000.00 to a high of 10,000.00. Based on the distribution chart, Coya Therapeutics ranks #4 out of 368 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Coya Therapeutics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coya Therapeutics' Interest Coverage compare to ONCY and GUTS?
According to the Biotechnology industry distribution chart, Coya Therapeutics ranks #4 out of 368 companies for Interest Coverage. This places Coya Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 98.26. Historically, Coya Therapeutics' own Interest Coverage has ranged from 10,000.00 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 98.26, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Coya Therapeutics and its competitors. For the Biotechnology industry, the median Interest Coverage is 98.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coya Therapeutics's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coya Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Coya Therapeutics (COYA) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.54, compared to a current price of $4.39 — trading 32.9% below its estimated fair value. The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Coya Therapeutics' overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Coya Therapeutics (COYA), the current Interest Coverage is No Debt (1) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coya Therapeutics (COYA) Overvalued in 2026?
Based on GuruFocus' analysis, Coya Therapeutics stock appears to be undervalued.
The current stock price of $4.39 is trading 32.9% below its estimated GF Value™ of $6.54.
GuruFocus considers Coya Therapeutics to be Significantly Undervalued.
Key valuation signals for COYA:
Interest Coverage: No Debt (1) (100% below median its 10-year median of 10,000.00)
GF Value™: $6.54 vs. price of $4.39 (32.9% below fair value)
No single metric tells the full story. See the COYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
49GF Score
Get the complete analysis for COYA
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COYA has been successfully added to your 
